Results · Apr-Jun 2026
Eris Lifesciences Q1 FY27 results
Sales grew 13% to ₹873 crore from ₹773 crore in Apr-Jun 2025.
Operating profit grew 7% to ₹296 crore, an operating margin of 33.9% (down 1.9 points from a year ago).
Net profit grew 15% to ₹143 crore from ₹125 crore in Apr-Jun 2025.
Against Jan-Mar 2026: sales +15%, net profit −49%.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 873.3 | 773.0 | +13% |
| Operating profit (EBITDA) | 296.2 | 276.7 | +7% |
| Operating margin | 33.9% | 35.8% | −1.9 pts |
| Net profit | 143.3 | 125.1 | +15% |
Consolidated figures. Margins & ratios change in percentage points (pts).
The last 7 quarters
From the company's results filed on BSE (Consolidated). Business numbers only. Education & analysis, not investment advice or a recommendation.